Match Group, Inc. (MTCH) Forms $46.66 Double Top; Celsion (CLSN) Shorts Lowered By 0.95%

Celsion Corporation (NASDAQ:CLSN) Logo

Celsion Corporation (NASDAQ:CLSN) had a decrease of 0.95% in short interest. CLSN’s SI was 1.11M shares in April as released by FINRA. Its down 0.95% from 1.12 million shares previously. With 171,200 avg volume, 7 days are for Celsion Corporation (NASDAQ:CLSN)’s short sellers to cover CLSN’s short positions. It closed at $2.21 lastly. It is down 35.14% since April 27, 2017 and is downtrending. It has underperformed by 46.69% the S&P500.

Match Group, Inc. (MTCH) formed double top with $49.46 target or 6.00% above today’s $46.66 share price. Match Group, Inc. (MTCH) has $12.83B valuation. The stock increased 2.91% or $1.32 during the last trading session, reaching $46.66. About 1.26M shares traded. Match Group, Inc. (NASDAQ:MTCH) has risen 175.06% since April 27, 2017 and is uptrending. It has outperformed by 163.51% the S&P500.

Analysts await Match Group, Inc. (NASDAQ:MTCH) to report earnings on May, 1. They expect $0.19 earnings per share, up 137.50% or $0.11 from last year’s $0.08 per share. MTCH’s profit will be $52.25M for 61.39 P/E if the $0.19 EPS becomes a reality. After $0.25 actual earnings per share reported by Match Group, Inc. for the previous quarter, Wall Street now forecasts -24.00% negative EPS growth.

Among 17 analysts covering Match Group (NASDAQ:MTCH), 11 have Buy rating, 0 Sell and 6 Hold. Therefore 65% are positive. Match Group has $395 highest and $9 lowest target. $45.63’s average target is -2.21% below currents $46.66 stock price. Match Group had 34 analyst reports since November 23, 2015 according to SRatingsIntel. The stock of Match Group, Inc. (NASDAQ:MTCH) earned “Neutral” rating by JP Morgan on Monday, December 14. The firm has “Buy” rating given on Monday, December 14 by Bank of America. The stock of Match Group, Inc. (NASDAQ:MTCH) has “Neutral” rating given on Friday, January 29 by Susquehanna. The company was downgraded on Thursday, February 4 by Barclays Capital. Barclays Capital initiated the stock with “Overweight” rating in Monday, December 14 report. On Tuesday, February 16 the stock rating was upgraded by BTIG Research to “Neutral”. The firm has “Buy” rating by Axiom Capital given on Monday, November 23. UBS maintained the stock with “Buy” rating in Thursday, November 9 report. The firm has “Buy” rating given on Tuesday, October 10 by Bank of America. The rating was maintained by Numis Securities on Thursday, November 3 with “Buy”.

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company has market cap of $39.21 million. The companyÂ’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It currently has negative earnings. It is also developing GEN-1, a DNA immunotherapeutic product for the localized treatment of ovarian and brain cancers.

Match Group, Inc. (NASDAQ:MTCH) Ratings Chart